Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Lipocine (LPCN) over the last 10 years, with Q3 2025 value amounting to $11.2 million.

  • Lipocine's Short-term Investments fell 3016.45% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year decrease of 3016.45%. This contributed to the annual value of $15.4 million for FY2024, which is 1063.73% down from last year.
  • Lipocine's Short-term Investments amounted to $11.2 million in Q3 2025, which was down 3016.45% from $11.9 million recorded in Q2 2025.
  • Lipocine's 5-year Short-term Investments high stood at $41.7 million for Q4 2021, and its period low was $11.2 million during Q3 2025.
  • In the last 5 years, Lipocine's Short-term Investments had a median value of $21.6 million in 2024 and averaged $24.3 million.
  • As far as peak fluctuations go, Lipocine's Short-term Investments surged by 915958.79% in 2021, and later crashed by 4124.25% in 2023.
  • Quarter analysis of 5 years shows Lipocine's Short-term Investments stood at $41.7 million in 2021, then fell by 29.49% to $29.4 million in 2022, then plummeted by 41.24% to $17.3 million in 2023, then dropped by 10.64% to $15.4 million in 2024, then fell by 27.21% to $11.2 million in 2025.
  • Its Short-term Investments was $11.2 million in Q3 2025, compared to $11.9 million in Q2 2025 and $16.4 million in Q1 2025.